MENS vs HALO vs ALNY vs AEYE vs IONS

For growth investors, Alnylam Pharmaceuticals, Inc.

(ALNY) is the stronger pick with 65. 2% revenue growth year-over-year, versus 14. 5% for AudioEye, Inc. (AEYE). Halozyme Therapeutics, Inc. (HALO) offers the better valuation at 25. 5x trailing P/E (8. 1x forward), making it the more compelling value choice. Analysts rate Halozyme Therapeutics, Inc. (HALO) a "Buy" — based on 27 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Halozyme Therapeutics, Inc.

(HALO) is the cheapest at 25. 5x versus Alnylam Pharmaceuticals, Inc. at 127. 0x. On forward P/E, Halozyme Therapeutics, Inc. is actually cheaper at 8. 1x.

Over the past 5 years, Alnylam Pharmaceuticals, Inc.

(ALNY) delivered a total return of +125. 4%, compared to -79. 7% for Jyong Biotech Ltd. Ordinary Shares (MENS). Over 10 years, the gap is even starker: HALO returned +570. 7% versus MENS's -79. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Ionis Pharmaceuticals, Inc.

(IONS) is the lower-risk stock at 0. 55β versus Jyong Biotech Ltd. Ordinary Shares's 2. 49β — meaning MENS is approximately 356% more volatile than IONS relative to the S&P 500. On balance sheet safety, AudioEye, Inc. (AEYE) carries a lower debt/equity ratio of 15% versus 5% for Ionis Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Alnylam Pharmaceuticals, Inc.

(ALNY) is pulling ahead at 65. 2% versus 14. 5% for AudioEye, Inc. (AEYE). On earnings-per-share growth, the picture is similar: Alnylam Pharmaceuticals, Inc. grew EPS 206. 9% year-over-year, compared to -25. 4% for Halozyme Therapeutics, Inc.. Over a 3-year CAGR, ALNY leads at 53. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Halozyme Therapeutics, Inc.

(HALO) is the more profitable company, earning 22. 7% net margin versus -40. 4% for Ionis Pharmaceuticals, Inc. — meaning it keeps 22. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus -40. 5% for IONS. At the gross margin level — before operating expenses — IONS leads at 98. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Halozyme Therapeutics, Inc.

(HALO) trades at 8. 1x forward P/E versus 44. 2x for Alnylam Pharmaceuticals, Inc. — 36. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ALNY: 50. 6% to $445. 67.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Halozyme Therapeutics, Inc.

(HALO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 56), +570. 7% 10Y return). Jyong Biotech Ltd. Ordinary Shares (MENS) carries a higher beta of 2. 49 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HALO: +570. 7%, MENS: -79. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (MENS (Healthcare) and HALO (Healthcare) and ALNY (Healthcare) and AEYE (Technology) and IONS (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: MENS is a small-cap quality compounder stock; HALO is a small-cap high-growth stock; ALNY is a mid-cap high-growth stock; AEYE is a small-cap quality compounder stock; IONS is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.